Bolt Biotherapeutics, Inc. Contract Liability (Deferred Revenue)
Bolt Biotherapeutics, Inc. (BOLT) had Contract Liability (Deferred Revenue) of $1.40 million as of 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-03-29
- 2022-12-31: Contract with Customer, Liability, Current $1.40M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-12-31 | $1.40M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |